Browsing by Author "Villanueva, L."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemEfficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer : the KEYNOTE-062 phase 3 randomized clinical trial(2020) Shitara, K.; Van Cutsem, E.; Bang, Y. J.; Fuchs, C.; Wyrwicz, L.; Lee, K.W.; Kudaba, I.; Garrido S., Marcelo; Chung, H. C.; Lee, J.; Castro, H. R.; Mansoor, W.; Braghiroli, M. I.; Karaseva, N.; Caglevic, C.; Villanueva, L.; Goekkurt, E.; Satake, H.; Enzinger, P.; Alsina, M.; Benson, A.; Chao, J.; Ko, A. H.; Wainberg, Z. A.; Kher, U.; Shah, S.; Kang, S. P.; Tabernero, J.
- ItemTumour necrosis factor (TNF)α-308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis(2006) Cuchacovich, M.; Soto, L.; Edwardes, M.; Gutierrez, M.; Llanos, C.; Pacheco, D.; Sabugo, F.; Alamo, M.; Fuentealba, C.; Villanueva, L.; Gatica, H.; Schiattino, I.; Salazar, L.; Catalan, D.; Valenzuela, O.Objective: To investigate the influence of -308 tumour necrosis factor-alpha (TNF alpha) promoter polymorphism and circulating TNF alpha levels in the clinical response to adalimumab treatment in patients with rheumatoid arthritis (RA).